Alivus Life Sciences Share Price

Pharmaceuticals company Alivus Life Sciences announced Q4FY26 & FY26 results Q4FY26 Financial Highlights: For Q4FY26, Revenue from operations was Rs. 6,891 million, a growth of 6.1% YoY. For Q4FY26, EBITDA was at Rs. 2,373 million, a growth of 13.8% YoY. EBITDA margins were at 34.4%, up 230 bps YoY. PAT for Q4FY26 stood at Rs. 1,627 million, a growth of 14.7% YoY and PAT margins were at 23.6%, up 180 bps YoY. FY26 Financial Highlights: For FY26, Alivus registered a Revenue from operations of Rs. 25,518 million, a growth of 6.9% YoY For FY26, EBITDA was at Rs. 8,577 million, a growth of 19.6% YoY. EBITDA margins were at 33.6%, up 360 bps YoY. PAT for FY26 stood at Rs. 5,645 million, a growth of 16.2% YoY and PAT margins were at 22.1%, up 180 bps YoY. During FY26, the company generated a strong free cash flow of Rs. 2,590 million leading to Cash and Cash Equivalents (including short term investments) of Rs. 7,824 million as of March 31, 2026. Business Higlights: DMF / CEP filings continue across major markets, taking the total cumulative filings to 611 as on March 31, 2026 The HP API portfolio has 28 APIs in the active grid with 12 products are validated, seven products are in advanced stages of development, remaining nine products progressing through lab development stages Capex Update: Solapur – Phase 1 and 1.1 construction work is in progress for 465 KL capacity To lead the future, we have acquired land in Taloja (Navi Mumbai) admeasuring 10,000 square meter to establish a state-of-the-art R&D; centre, designed to advance complex chemistry and oncology research. The centre will focus on flow chemistry, complex products, particle engineering and green chemistry, strengthening our pipeline across key therapeutic areas. Construction work in our new R&D; facility has commenced. Yasir Rawjee, MD & CEO, Alivus Life Sciences said, “The past two years under Nirma's ownership have been deeply fulfilling — a period of transition and evolution that has strengthened the foundation of the business and positioned us decisively for the next phase of sustainable growth. Coming to our results, FY26 reflected a clear improvement in our operating performance. Revenue grew 6.9% year-on-year, supported by growth in non-GPL business of 13%, which resulted in EBITDA growth of 19.6%. Encouragingly, the CDMO business delivered the turnaround we had planned in the second half, closing the year with 18% YoY growth. We also witnessed healthy momentum across key geographies like India, Europe, ROW, Japan and LATAM, while the GPL business de-grew by 4.9%. For FY27, we remain confident of delivering high single-digit revenue growth, with margins sustained above 30%, supported by improving operating leverage and a rising contribution from new products.” Tushar Mistry, CFO, Alivus Life Sciences said, “We continued our strong growth momentum in Q4FY26, delivering 6.1% year-on-year revenue growth. We ended FY26 with 6.9% growth. The performance was broad-based, with contributions from almost all regions. At Alivus, we remain focused on profitable growth, reflected in the improvement in both, our Gross and EBITDA margins during the quarter. For the full year, we reported EBITDA margins of 33.6%, exceeding our guided range of 30–32%, driven by a favourable product mix and disciplined control over operating expenses. The year has ended with strong operating cash flows, providing us ample flexibility to support our growth initiatives while maintaining a healthy, debt-free balance sheet.” Result PDF

• Trendlyne
• 1 month ago

Conference Call with Alivus Life Sciences Management and Analysts on Q4FY26 & Full Year Performance and Outlook. Listen to the full earnings transcript.

• Trendlyne
• 1 month ago

Conference Call with Alivus Life Sciences Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.

• Trendlyne
• 4 months 3 weeks ago